Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Loredana Militello

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancyDiana Crivellari, Loredana Militello
Genes & Cancer|September 10, 2010
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN CircuitKimberly Lin, Stavroula Baritaki, Loredana Militello, et al.
International Journal of Oncology|April 2, 2011
The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosisStavroula Baritaki, Loredana Militello, Graziella Malaponte, et al.
Radiology and Oncology|March 2, 2013
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studiesAlessandro Tuzi, Davide Lombardi, Diana Crivellari, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Understanding rituximab function and resistance: implications for tailored therapyAlfredo Amoroso, Sameh Hafsi, Loredana Militello, et al.
Tumori|February 18, 2015
Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experiencePaolo Carli, Loredana Militello, Gian Maria Miolo, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
The involvement of the transcription factor Yin Yang 1 in cancer development and progressionGiancarlo Castellano, Elena Torrisi, Giovanni Ligresti, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approachesGiovanni Ligresti, Loredana Militello, Linda S Steelman, et al.
Molecular Medicine Reports|April 12, 2011
Breast cancer: Molecular basis and therapeutic strategies (Review)Giovanni Ligresti, Massimo Libra, Loredana Militello, et al.
Tumori|April 13, 2012
Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experienceDiana Crivellari, Simon Spazzapan, Davide Lombardi, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancyDiana Crivellari, Loredana Militello
Genes & Cancer|September 10, 2010
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN CircuitKimberly Lin, Stavroula Baritaki, Loredana Militello, et al.
International Journal of Oncology|April 2, 2011
The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosisStavroula Baritaki, Loredana Militello, Graziella Malaponte, et al.
Radiology and Oncology|March 2, 2013
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studiesAlessandro Tuzi, Davide Lombardi, Diana Crivellari, et al.
Frontiers in Bioscience (Landmark Edition)|January 4, 2011
Understanding rituximab function and resistance: implications for tailored therapyAlfredo Amoroso, Sameh Hafsi, Loredana Militello, et al.
Tumori|February 18, 2015
Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experiencePaolo Carli, Loredana Militello, Gian Maria Miolo, et al.
Cell Cycle (Georgetown, Tex.)|April 4, 2009
The involvement of the transcription factor Yin Yang 1 in cancer development and progressionGiancarlo Castellano, Elena Torrisi, Giovanni Ligresti, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approachesGiovanni Ligresti, Loredana Militello, Linda S Steelman, et al.
Molecular Medicine Reports|April 12, 2011
Breast cancer: Molecular basis and therapeutic strategies (Review)Giovanni Ligresti, Massimo Libra, Loredana Militello, et al.
Tumori|April 13, 2012
Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experienceDiana Crivellari, Simon Spazzapan, Davide Lombardi, et al.
Pageof 2